Indeed, AdipoRon tended to reduce the expression of adipose triglyceride lipase (Pnpla2), the rate‐limiting enzyme of lipolysis in adipose tissue, and to alleviate the enhanced hepatic fatty acid uptake and triglyceride synthesis by the liver, as indicated by lower Cd36 and Gpat1 expression, respectively, therefore contributing to lowering hypertriglyceridaemia. The gene discussed is PNPLA2; the disease is hypertriglyceridemia.